OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
NEW YORK, Dec. 04, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Zafgen, Inc. (Nasdaq:ZFGN) securities between January 12, 2015 and October 16, 2015.
Click here to learn about the case: http://docs.wongesq.com/ZFGN-Info-Request-Form-971. There is no cost or obligation to you.
The lawsuit alleges that Defendants made misrepresentations about thrombotic adverse events in previous clinical trials of its anti-obesity drug, and leading drug candidate, beloranib. Until October 16, 2015, Zafgen had disclosed only two thrombotic adverse events in one prior clinical trial.
On October 14, 2015, Zafgen issued a statement acknowledging the death of a patient in its ongoing Phase 3 study of beloranib. On October 15, 2015, the Food and Drug Administration informed Zafgen that beloranib had been placed on partial clinical hold. Then on October 16, 2015, Zafgen announced that: (i) the patient who died was receiving beloranib – not a placebo; and (ii) there had been four thrombotic adverse events in prior clinical studies of beloranib – two more than previously reported – as well as two additional, previously undisclosed thrombotic events in ongoing studies.
If you suffered a loss in Zafgen you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ZFGN-Info-Request-Form-971.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
